Quick Order Cart

Cat. No. ARG0829

USP10 Knockout THP-1 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

  • Gene Species:

    Homo sapiens (Human)

The USP10 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line targeting the deubiquitinase USP10 in the human THP-1 monocytic leukemia background. USP10 stabilizes p53 and activates autophagy by deubiquitinating Beclin1, playing critical roles in DNA damage response and stress signaling. This model enables investigation of p53-dependent apoptosis, autophagy regulation, and ubiquitin-mediated signaling in a monocytic leukemia context. Key applications include evaluating DNA damage responses, drug sensitivity, and autophagy flux using techniques such as Western blotting, RT-qPCR, and flow cytometry. The cell line provides a stable, disease-relevant platform for dissecting USP10 function in leukemogenesis and stress adaptation.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Age

    1 year

    Sex of Donor

    Male

    Gene Name

    USP10

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 9100

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The USP10 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line featuring targeted disruption of the USP10 gene in the human THP-1 monocytic leukemia cell background. This loss-of-function model is designed for investigations into the deubiquitinase USP10 and its roles in p53-dependent stress responses, autophagy regulation, and ubiquitin-mediated signaling pathways. The engineered cell line enables stable, long-term studies without the transient effects of siRNA or pharmacological inhibition, providing a reliable platform for mechanistic and drug-sensitivity assays.

The parental THP-1 cell line was derived from the peripheral blood of a human male infant with acute monocytic leukemia and is widely used as a monocyte/macrophage progenitor model. THP-1 cells can be differentiated into macrophage-like cells, making them a versatile system for studying monocytic differentiation, innate immune functions, and leukemogenesis. This disease-relevant context is ideal for evaluating tumor-suppressive mechanisms and therapeutic vulnerabilities associated with USP10 disruption.

USP10 encodes a deubiquitinase that removes ubiquitin chains from target proteins, controlling their stability and activity. ATM kinase activates USP10 following DNA damage, leading to deubiquitination and stabilization of p53, which transcriptionally induces CDKN1A and BAX to promote cell cycle arrest and apoptosis. USP10 also deubiquitinates Beclin1, a key component of the Vps34/PI3K complex, to positively regulate autophagy initiation. Additional interacting factors include G3BP1 and AR, linking USP10 to stress granule dynamics and NF-??B signaling through IKK?? modulation. Knockout of USP10 disrupts these events, impairing p53-mediated checkpoint control and autophagic flux.

In the THP-1 monocytic leukemia background, loss of USP10 function attenuates p53-dependent apoptotic responses to genotoxic agents and compromises autophagy-mediated stress adaptation. This model allows dissection of how deubiquitinase activity governs leukemic cell survival, differentiation, and drug sensitivity. Since THP-1 cells retain functional p53, the USP10 knockout line is suited for examining crosstalk between ubiquitin editing and p53-driven tumor suppression in a hematological malignancy.

This knockout cell line supports a broad range of applications. Researchers can use Western blotting to assess USP10, p53, and LC3-II levels, RT-qPCR for CDKN1A and BAX transcripts, flow cytometry with Annexin V for apoptosis, and immunofluorescence for ??H2AX foci after etoposide treatment to probe DNA damage responses. Autophagy flux assays with bafilomycin A1 and co-immunoprecipitation of USP10-Beclin1 further elucidate mechanism. These approaches enable investigation of DNA damage responses in leukemia, autophagy in monocytic cells, p53-dependent drug sensitivity, and ubiquitin signaling in immune cells. For additional information or technical support, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)